Pirtobrutinib
Pirtobrutinib (LOXO-305) is a highly selective, non-covalent BTK inhibitor effective against C481 mutations. It demonstrates potent anti-tumor activity in BTK-dependent lymphoma models in vivo and shows exceptional kinase selectivity. This molecule is a valuable research tool for studying B-cell malignancies and resistance mechanisms in both cellular and animal studies.
Product Specifications
CAS Number
2101700-15-4
Product Name Alternative
Inhibitor, LOXO 305, LOXO305, LOXO-305, inhibit, mutations, C81S, Bruton tyrosine kinase, BTK, Btk, autophosphorylation, proliferative, Pirtobrutinib
Field of Research
Cardiovascular Research, Signal Transduction
Purity
99.76% (May vary between batches)
Solubility
DMSO:250 mg/mL (521.45 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.17 mM)
Smiles
COc1ccc (F) cc1C (=O) NCc1ccc (cc1) -c1nn ([C@@H] (C) C (F) (F) F) c (N) c1C (N) =O
Molecular Formula
C22H21F4N5O3
Molecular Weight
479.43
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
DUSP28 Human qPCR Primer Pair (NM_001033575)
